早期应用双磷酸盐在晚期前列腺癌治疗中的作用

Effect of Early Application of Bisphosphonates in the Treatment of Advanced Prostatic Carcinoma

目的探讨早期静脉应用双磷酸盐对晚期前列腺癌进展及骨转移发生时间的影响。方法随机选择2014年12月—2016年12月期间该院收治的40例晚期前列腺癌患者作为研究对象,并随机分为观察组和对照组,两组患者均给予常规治疗,对照组未早期应用双磷酸盐,观察组给予早期应用双磷酸盐,观察两组患者的无进展生存期、骨转移发生率、骨转移发生时间、总生存期等、不良反应发生情况。结果观察组的平均无进展生存期为(20.3±0.6)个月,对照组的平均无进展生存期为(15.3±1.6)个月,组间比较差异有统计学意义(t=0.365,P=0.025);观察组患者的骨转移率(20.0%)显著高于对照组(60.0%),差异有统计学意义(χ~2=1.014,P=0.000),且骨转移时间较对照组延迟近4个月,两组的骨转移时间和骨转移发生率比较差异有统计学意义(t=0.897,P=0.004;t=3.365,P=0.014)。结论早期应用双磷酸盐治疗晚期前列腺癌能够显著缓解疾病进程,降低骨转移患者发生骨相关事件的发生几率,延长患者的生命周期和生存质量。

Objective To study the effect of early intravenous application of bisphosphonates on the progress of advanced prostatic carcinoma and occurrence time of osseous metastasis. Methods 40 cases of patients with advanced prostatic carcinoma admitted and treated in our hospital from December 2014 to December 2016 were randomly selected and randomly divided into two groups, both groups were given the routine treatment, the control group did not apply the bisphosphonates in the early stage, while the observation group adopted the early application of bisphosphonates, and the progression-free survival, incidence rate of osseous metastasis, occurrence time of osseous metastasis, total survival and occurrence of adverse reactions of the two groups were observed. Results The difference in the average progression-free survival between the observation group and the control group was statistically significant [(20.3 ±0.6)months vs(15.3 ±1.6)months](t =0.365,P =0.025), and the osseous metastasis rate in the observation group was obviously higher than that in the control group(20.0%vs 60.0%), and the difference was statistically significant(χ~2=1.014,P =0.000), and the osseous metastasis time was longer for four months than that in the control group, and the differences in the osseous metastasis time and incidence rate of osseous metastasis between the two groups were statistically significant(t=0.897,P=0.004;t=3.365,P=0.014). Conclusion The early application of bisphosphonates in the treatment of advanced prostatic carcinoma can obviously relieve the disease progress, reduce the occurrence probability of bone related events of patients with osseous metastasis and prolong the life cycle and survival quality of patients.